CURE CBD Position Statement
Three million Americans currently live with epilepsy. Of these, one-third of patients do not respond to any of the currently available treatments. Most people cannot imagine the horror of watching a loved one have even one seizure; yet 1 in 26 Americans will develop epilepsy in their lifetime.
As the leading private funder of epilepsy research, CURE recognizes the emerging need for scientifically rigorous investigations into the mechanisms and efficacy of cannabidiol (CBD) for the treatment of epilepsy. It is important to clarify that many believe it is CBD (the non-psychoactive component of "medical marijuana”) that helps patients.
As interest grows, CURE anticipates and welcomes research proposals by qualified biomedical researchers that will accelerate the discovery of transformative, disease-modifying therapies for patients and families. This includes investigations into the effectiveness of using CBD to treat various syndromes of epilepsy. At present, CURE's research portfolio does not include studies in this area.
Several states are now addressing legal issues surrounding the disbursement and prescription of CBD and CURE applauds all efforts focused on addressing potential treatments and cures for epilepsy. With a lack of scientific evidence on the usefulness and safety of CBD as a treatment for epilepsy, CURE strongly encourages those touched by epilepsy to work with their treating physicians to make the best decisions for their own or loved ones’ care.
For further information or questions about CURE's research initiatives and programs, please contact H. Steve White, PhD, Research Director, at steve@CUREepilepsy.org.
For general organization inquiries, please contact Samantha Kreindel, Communications Director, at samantha@CUREepilepsy.org.
Download this article as a PDF here.